Results of the Statin Domain in REMAP-CAP Trial

This chapter discusses the findings of the statin domain in the REMAP-CAP trial, focusing on the efficacy of Simvastatin in COVID-19. It explores the rationale behind choosing statins as an intervention and highlights their anti-inflammatory effects. The chapter also discusses the trial's design, eligibility criteria, interactions with other therapies, and the decision to stop the trial early.